Table 2 VASP-PRI data in the 5 treatment cohorts
Upstream clopidogrel | Upstream clopidogrel-prasugrel switch | Prasugrel cath lab | Upstream clopidogrel-ticagrelor switch | Upstream ticagrelor | |
|---|---|---|---|---|---|
Pre-PCI VASP | 74% (SD 19) | 79% (SD 13) | 80% (SD 15) | 79% (SD 16) | 64% (SD 29) |
Post-PCI VASP | 74% (SD 20) | 74% (SD 21) | 69% (SD 34) | 77% (SD 20) | 53% (SD 30) |
Day after PCI VASP | 56% (SD 27) | 17% (SD 21) | 19% (SD 18) | 15% (SD 8) | 29% (SD 25) |
Percentage of patients with VASP-PRI <50% day after PCI | 32% | 90% | 91% | 100% | 83% |